BILISTICK A low cost point of care for early diagnosis of hyperbilirubinemia in...
BILISTICK A low cost point of care for early diagnosis of hyperbilirubinemia in newborns
The objective of the overall project is to lead to the international market Bilistick, an innovative low-cost Point-of-Care for early diagnosis of hyperbilirubinemia. The system aims to prevent, through early diagnosis, the perman...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
Picterus
A remote and price efficient tool for jaundice screening
71K€
Cerrado
RETOXY
Clinical validation of retinal oximetry as a biomarker
71K€
Cerrado
PREVENTIT
ASSURED Point of Care Device for Syphilis and HIV in Pregnan...
3M€
Cerrado
PLATINUM
Portable Diagnostic Medical Device Based on Lab on Chip for...
3M€
Cerrado
INNOHEM
Innovative 5 part haematology analyser for near patient diag...
71K€
Cerrado
Información proyecto BILISTICK
Duración del proyecto: 7 meses
Fecha Inicio: 2015-12-17
Fecha Fin: 2016-07-31
Líder del proyecto
BILIMETRIX SRL
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The objective of the overall project is to lead to the international market Bilistick, an innovative low-cost Point-of-Care for early diagnosis of hyperbilirubinemia. The system aims to prevent, through early diagnosis, the permanent neurological damage that severe hyperbilirubinemia can cause in newborns.Every year in European Union there are about 3 thousands cases of kernicterus (worst consequence of hyperbilirubinemia) determining consequent huge costs for National Healthcare Systems.
Kernicterus is a largely preventable disease if severe hyperbilirubinemia is identified early and promptly treated. For this reason AAP Guidelines (adopted by EU) recommend universal bilirubin screening and individualized post-discharge follow-up care based on results of such screening. However existing solutions are expensive, not portable or not enough accurate.
Bilistick is the only in vitro rapid diagnostic device for measuring the level of bilirubin in the blood of newborns. It is low cost, minimally invasive, portable, giving rapid response, accurate and applicable in all newborns. It is the result of experience acquired during years of academic and professional research carried out by the entrepreneurial team of Bilimetrix s.r.l.. Bilimetrix s.r.l. is a spin-off of the University of Trieste, established as a research and development company. Its core business is development of medical devices based on advanced technologies oriented on liver, kidney and heart dis-functions. All solution are mainly based on new biomarkers.
The purpose of the feasibility study is a comprehensive examination of all aspects of feasibility of the project, from the technical to the economical viewpoint, converging in a detailed business plan for application in Phase 2. Emphasis will be put on market analysis (nature of the market, type of users, competitors in the market, pricing systems, methods of distribution and marketing) and then on examination of the market acceptance towards Bilistick